DLBCL - Diffuse Large B Cell Lymphoma Clinical Trials

21 recruiting

DLBCL - Diffuse Large B Cell Lymphoma Trials at a Glance

21 actively recruiting trials for dlbcl - diffuse large b cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in New York, Rotterdam, and Groningen. Lead sponsors running dlbcl - diffuse large b cell lymphoma studies include Memorial Sloan Kettering Cancer Center, The First Affiliated Hospital of Xiamen University, and Australasian Leukaemia and Lymphoma Group.

Browse dlbcl - diffuse large b cell lymphoma trials by phase

Treatments under study

About DLBCL - Diffuse Large B Cell Lymphoma Clinical Trials

Looking for clinical trials for DLBCL - Diffuse Large B Cell Lymphoma? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new DLBCL - Diffuse Large B Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about DLBCL - Diffuse Large B Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting
Early Phase 1

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaB-cell Non Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT07548697
Recruiting

Glofitamab in Chinese Patients With R/R DLBCL

DLBCL - Diffuse Large B Cell Lymphoma
Peking Union Medical College Hospital20 enrolled1 locationNCT06481826
Recruiting
Phase 2

CAR-T Followed by Bispecific Antibodies

DLBCL - Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Abramson Cancer Center at Penn Medicine42 enrolled2 locationsNCT04889716
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting
Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 1

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 2

DALY II Japan/MB-CART2019.1 for DLBCL

DLBCL - Diffuse Large B Cell Lymphoma
Miltenyi Biomedicine GmbH31 enrolled5 locationsNCT07288879
Recruiting
Phase 3

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

DLBCL - Diffuse Large B Cell Lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland324 enrolled25 locationsNCT06220032
Recruiting
Phase 2

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaStage III High Grade B-Cell Lymphoma+7 more
Memorial Sloan Kettering Cancer Center50 enrolled7 locationsNCT06736613
Recruiting
Phase 1

Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta

DLBCL - Diffuse Large B Cell Lymphoma
University Health Network, Toronto40 enrolled1 locationNCT05950802
Recruiting
Phase 2

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

DLBCL - Diffuse Large B Cell Lymphoma
The First Affiliated Hospital of Soochow University29 enrolled1 locationNCT07255963
Recruiting
Not Applicable

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoma, B-Cell+3 more
Memorial Sloan Kettering Cancer Center48 enrolled2 locationsNCT05940272
Recruiting

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

DLBCL - Diffuse Large B Cell LymphomaMarkers of Inflammation
Ain Shams University40 enrolled1 locationNCT07057765
Recruiting
Phase 2

Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

DLBCL - Diffuse Large B Cell LymphomaChidamideR-CHOP Chemotherapy+1 more
The First Affiliated Hospital with Nanjing Medical University148 enrolled1 locationNCT06891157
Recruiting
Phase 2

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL

DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma
The First Affiliated Hospital of Xiamen University38 enrolled1 locationNCT06151080
Recruiting
Phase 2

AZA Combined With RCHOP in P53-mutated DLBCL.

DLBCL - Diffuse Large B Cell LymphomaTP53
The First Affiliated Hospital of Xiamen University52 enrolled1 locationNCT06158399
Recruiting

Real-World Study of DLBCL With Different Genetic Subtypes

DLBCL - Diffuse Large B Cell LymphomaLymphoma
Ruijin Hospital10,000 enrolled1 locationNCT06026488
Recruiting
Phase 2

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

DLBCL - Diffuse Large B Cell LymphomaNHL
University Medical Center Groningen300 enrolled7 locationsNCT05641428
Recruiting

Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

DLBCL - Diffuse Large B Cell Lymphoma
University Medical Center Goettingen500 enrolled1 locationNCT06526065
Recruiting
Phase 2

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+4 more
Australasian Leukaemia and Lymphoma Group39 enrolled1 locationNCT06287398